Chengdu Kanghua Biological Products Co., Ltd. (SHE:300841)
China · Delayed Price · Currency is CNY 46.82
+0.63 (1.36%)
Aug 4, 2026, 3:04 PM CST
SHE:300841 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 6,084 | 9,390 | 6,992 | 10,371 | 11,318 | 19,145 | |
Market Cap Growth | -41.05% | 34.30% | -32.58% | -8.37% | -40.88% | -31.86% |
Enterprise Value | 5,059 | 8,597 | 6,446 | 9,762 | 10,870 | 18,215 |
Last Close Price | 46.82 | 71.50 | 52.92 | 72.99 | 79.18 | 131.10 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 26.86 | 42.70 | 17.54 | 20.37 | 18.92 | 23.08 |
Forward PE | 22.51 | 16.18 | 9.79 | 15.93 | 8.63 | 25.46 |
PS Ratio | 5.07 | 8.06 | 4.88 | 6.58 | 7.82 | 14.81 |
PB Ratio | 1.71 | 2.65 | 2.03 | 2.95 | 3.68 | 7.17 |
P/TBV Ratio | 1.71 | 2.67 | 2.04 | 2.96 | 3.70 | 7.22 |
P/FCF Ratio | 16.92 | 30.40 | 16.34 | 24.89 | - | - |
P/OCF Ratio | 14.58 | 24.73 | 12.22 | 18.07 | 58.04 | 146.90 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 4.22 | 7.38 | 4.50 | 6.19 | 7.51 | 14.09 |
EV/EBITDA Ratio | 15.21 | 26.88 | 10.80 | 14.99 | 16.90 | 28.96 |
EV/EBIT Ratio | 19.68 | 34.91 | 12.12 | 16.26 | 17.77 | 29.67 |
EV/FCF Ratio | 14.07 | 27.83 | 15.06 | 23.43 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.01 | 0.04 | 0.05 | 0.05 | 0.04 | 0 |
Debt / EBITDA Ratio | 0.09 | 0.44 | 0.31 | 0.29 | 0.20 | 0.00 |
Debt / FCF Ratio | 0.08 | 0.45 | 0.44 | 0.46 | - | - |
Net Debt / Equity Ratio | -0.29 | -0.29 | -0.24 | -0.24 | -0.17 | -0.35 |
Net Debt / EBITDA Ratio | -3.08 | -3.16 | -1.36 | -1.30 | -0.82 | -1.47 |
Net Debt / FCF Ratio | -2.85 | -3.27 | -1.90 | -2.04 | 2.34 | 5.02 |
Asset Turnover | 0.31 | 0.29 | 0.35 | 0.40 | 0.43 | 0.50 |
Inventory Turnover | 0.64 | 0.64 | 0.48 | 0.64 | 0.79 | 1.10 |
Quick Ratio | 7.36 | 5.41 | 4.06 | 3.62 | 3.20 | 5.21 |
Current Ratio | 7.89 | 5.74 | 4.39 | 3.90 | 3.51 | 5.73 |
Return on Equity (ROE) | 6.44% | 6.30% | 11.45% | 15.46% | 20.82% | 35.72% |
Return on Assets (ROA) | 4.13% | 3.83% | 8.07% | 9.48% | 11.37% | 14.86% |
Return on Invested Capital (ROIC) | 8.54% | 8.08% | 17.13% | 20.43% | 24.92% | 46.87% |
Return on Capital Employed (ROCE) | 7.10% | 6.90% | 15.40% | 17.00% | 19.70% | 22.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 3.72% | 2.34% | 5.70% | 4.91% | 5.28% | 4.33% |
FCF Yield | 5.91% | 3.29% | 6.12% | 4.02% | -1.98% | -0.96% |
Dividend Yield | 1.08% | 0.70% | 1.89% | 2.74% | 0.63% | 0.76% |
Payout Ratio | 58.65% | 62.04% | 67.18% | 14.07% | 22.88% | 10.85% |
Buyback Yield / Dilution | 0.64% | 1.30% | 1.56% | 0.17% | 0.46% | -13.94% |
Total Shareholder Return | 1.72% | 2.00% | 3.45% | 2.91% | 1.09% | -13.17% |